Abstrak 
Use of BRAF V600E as a Molecular Marker in Aggressive Colorectal Cancer
Bethy S. Hernowo, Fenny Ariyanni, Sri Suryanti, Abdul H. Hassan
Universitas Padjadjaran, Acta Medica Indonesiana - The Indonesian Journal of Internal Medicine Vol 46 • Number 2 • April 2014
Bahasa Indonesia, Bahasa Inggris
Universitas Padjadjaran, Acta Medica Indonesiana - The Indonesian Journal of Internal Medicine Vol 46 • Number 2 • April 2014
BRAF V600E, colorectal carcinoma., Dukes, immunoexpression, imunoekspresi, karsinoma kolorektal
Tujuan: meneliti perbedaan imunoekspresi BRAF V600E di antara stadium Dukes pada karsinoma kolorektal. Metode: penelitian ini retrospektif, potong lintang, terhadap kasus karsinoma kolorektal masing-masing stadium Dukes A, B dan C sebanyak 15 kasus. Dilakukan pewarnaaan antibodi BRAF V600E terhadap potongan tipis massa tumor untuk mengevaluasi adanya protein BRAF V600E. Perbedaan proporsi imunoekspresi BRAF V600E di antara masing-masing stadium Dukes pada karsinoma kolorektal diuji menggunakan uji Chi-Square. Hasil: hasil pewarnaan imunohistokimia yang positif (positif sedang sampai positif kuat) pada stadium Dukes A, B, C adalah sebagai berikut: 1 kasus dari 15, 4 kasus dari 15 kasus dan 13 kasus dari 15 kasus. Pewarnaan imunohistokimia BRAF V600E yang positif lebih banyak ditemukan pada stadium Dukes C dan sangat bermakna (p<0,001) berdasarkan uji statistik Chi-Square. Kesimpulan: hasil pewarnaan imunohistokimia BRAF V600E dapat dipakai sebagai petanda karsinoma kolorektal yang lebih agresif. Aim: to compare the immunoexpression of BRAF V600E among stage of colorectal cancer. Methods: this was a cross sectional, and retrospective study involving Dukes’ stage A, B, and C colorectal carcinoma, each with 15 cases. Immunohistochemistry was performed in paraffin-embedded specimens of tumor mass for the assessment of BRAF V600E. The proportion differences of immunoexpression of BRAF V600E among Dukes’stage A, B, and C were tested using Chi-Square test. Results: the result of positive BRAF V600E immunoexpression (moderately to strongly positive) in Dukes’stage A, B, and C were found in 1 of 15 cases, 4 of 15 cases and 13 of 15 cases respectively. BRAF V600E immunoexpression was statistically significant more frequent in Dukes’stage C (p<0,001, Chi-Square test). Conclusion: positive BRAF V600E immunoexpression could be used as a marker of aggresive colorectal carcinoma.